Kenvue Inc.KVUE
NYSE•Consumer Defensive•Household & Personal Products
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Kenvue Inc. (KVUE) reported trailing twelve months revenue of $15.29B as of March 2026, a 0.1% decline year-over-year. Quarterly revenue reached $3.91B, reflecting a contraction in sales.
Kenvue Inc. generated $1.62B in TTM net income, with quarterly EBITDA of $910.00M. The operating margin expanded from 14.9% to 19.6%, suggesting improving cost efficiency and pricing discipline.
The spread between operating margin (19.6%) and net margin (12.1%) indicates moderate non-operating costs. Net margin has improved from 8.6% a year ago, signaling stronger bottom-line efficiency.
KVUE trades at a P/E of 20.7x (in line with broad market averages) and a P/S of 2.2x. The price-to-book ratio of 3.2x reflects a moderate premium to book value.
The company generated $350.00M in free cash flow over the trailing twelve months, a 40.6% increase year-over-year, indicating cash generation ability. The balance sheet shows $26.85B in total assets with $7.07B in long-term debt against $10.61B in stockholders equity for a debt-to-equity ratio of 0.7. Data based on the most recent quarterly reports.
Competitive analysis based on 13 quarters of fundamental data
Operating margins are expanding at ~14.7%, suggesting durable pricing power and cost discipline.
ROE is positive at ~12.6% on average, adequate but below the threshold typically associated with wide moats.
Free cash flow is consistently positive and growing — a hallmark of a capital-light business that can self-fund growth.
Revenue has been flat or declining over recent quarters, which may indicate eroding demand or competitive pressure.
Data-driven red flags and warnings across 13 quarters
Margins are stable or improving at ~17.1% — no sign of cost or pricing stress.
FCF covers net income by 1.8x on average — earnings are well-supported by cash generation.
D/E ratio is 0.7 — conservative capital structure with low financial risk.
Revenue has softened, declining in 5 quarters. Monitor for further erosion.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Share count is stable — no significant dilution or buyback activity.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation